Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astrazeneca Plc stock logo
AZN
Astrazeneca
$184.07
+1.6%
$195.55
$132.32
$212.71
$285.47B0.262.73 million shs719,657 shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$223.57
-0.9%
$238.49
$146.12
$251.71
$538.42B0.278.44 million shs2.48 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$48.52
+3.9%
$51.77
$22.28
$59.55
$19.15B1.059.56 million shs1.83 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.29
-0.6%
$27.17
$21.97
$28.75
$149.52B0.3542.59 million shs14.59 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$718.84
+2.4%
$755.26
$476.49
$821.11
$76.02B0.3740,964 shs229,631 shs
Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astrazeneca Plc stock logo
AZN
Astrazeneca
-1.77%-2.89%-10.80%-3.25%+25.79%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-0.84%-0.91%-7.14%-3.70%+45.53%
Moderna, Inc. stock logo
MRNA
Moderna
+2.95%-0.91%-5.06%+9.21%+67.78%
Pfizer Inc. stock logo
PFE
Pfizer
+0.29%-0.09%-6.85%-1.52%+10.73%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+0.15%-4.01%-7.80%-9.39%+16.38%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astrazeneca Plc stock logo
AZN
Astrazeneca
$184.07
+1.6%
$195.55
$132.32
$212.71
$285.47B0.262.73 million shs719,657 shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$223.57
-0.9%
$238.49
$146.12
$251.71
$538.42B0.278.44 million shs2.48 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$48.52
+3.9%
$51.77
$22.28
$59.55
$19.15B1.059.56 million shs1.83 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.29
-0.6%
$27.17
$21.97
$28.75
$149.52B0.3542.59 million shs14.59 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$718.84
+2.4%
$755.26
$476.49
$821.11
$76.02B0.3740,964 shs229,631 shs
Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astrazeneca Plc stock logo
AZN
Astrazeneca
-1.77%-2.89%-10.80%-3.25%+25.79%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-0.84%-0.91%-7.14%-3.70%+45.53%
Moderna, Inc. stock logo
MRNA
Moderna
+2.95%-0.91%-5.06%+9.21%+67.78%
Pfizer Inc. stock logo
PFE
Pfizer
+0.29%-0.09%-6.85%-1.52%+10.73%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+0.15%-4.01%-7.80%-9.39%+16.38%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astrazeneca Plc stock logo
AZN
Astrazeneca
2.85
Moderate Buy$205.3311.55% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.67
Moderate Buy$252.4812.93% Upside
Moderna, Inc. stock logo
MRNA
Moderna
1.84
Reduce$35.73-26.35% Downside
Pfizer Inc. stock logo
PFE
Pfizer
2.23
Hold$28.749.33% Upside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.77
Moderate Buy$826.5914.99% Upside

Current Analyst Ratings Breakdown

Latest MRNA, PFE, AZN, JNJ, and REGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$36.00 ➝ $45.00
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetSector Perform$35.00 ➝ $38.00
5/4/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Reiterated RatingBuy
5/1/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$43.00 ➝ $49.00
5/1/2026
Moderna, Inc. stock logo
MRNA
Moderna
Set Price Target$33.00
5/1/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Boost Price TargetBuy$975.00 ➝ $995.00
4/30/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Reiterated RatingBuy
4/30/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Reiterated RatingSell
4/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Lower Price TargetSector Perform$779.00 ➝ $762.00
4/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Lower Price TargetOverweight$923.00 ➝ $917.00
4/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Lower Price TargetBuy$801.00 ➝ $796.00
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astrazeneca Plc stock logo
AZN
Astrazeneca
$58.74B4.86$12.97 per share14.19$30.55 per share6.03
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$94.19B5.71$14.08 per share15.88$33.73 per share6.63
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B9.86N/AN/A$18.76 per share2.59
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.39$4.40 per share5.98$15.26 per share1.72
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.34B5.30$42.53 per share16.90$297.23 per share2.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astrazeneca Plc stock logo
AZN
Astrazeneca
$10.23B$5.9127.6415.991.5117.19%30.86%12.68%N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$26.80B$8.6525.8617.772.2021.83%32.60%13.29%7/15/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3619.339.32N/A12.42%20.48%8.86%N/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.50B$41.0417.5217.321.5829.65%13.16%10.17%N/A

Latest MRNA, PFE, AZN, JNJ, and REGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7220$0.75+$0.0280$0.47$13.84 billion$14.45 billion
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
4/29/2026Q1 2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
$2.52$2.58+$0.06$0.9850$14.93 billion$15.29 billion
4/29/2026Q1 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$8.91$9.47+$0.56$6.75$3.48 billion$3.61 billion
4/14/2026Q1 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billion
2/13/2026Q4 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.79-$2.11+$0.68-$2.11$611.14 million$678.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Astrazeneca Plc stock logo
AZN
Astrazeneca
$4.342.39%+2.30%73.43%N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.202.31%+5.25%60.12%64 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.51%-13.20%126.47%16 Years
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.760.54%N/A9.16%N/A

Latest MRNA, PFE, AZN, JNJ, and REGN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.42%5/8/20265/8/20266/12/2026
4/14/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.342.23%5/26/20265/26/20266/9/2026
4/29/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.940.55%5/20/20265/20/20266/4/2026
2/10/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
$1.59501.56%2/20/20262/20/20263/23/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astrazeneca Plc stock logo
AZN
Astrazeneca
0.52
0.91
0.71
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.46
1.03
0.77
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
Pfizer Inc. stock logo
PFE
Pfizer
0.71
1.16
0.87
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.06
3.57
2.96

Institutional Ownership

CompanyInstitutional Ownership
Astrazeneca Plc stock logo
AZN
Astrazeneca
20.35%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%

Insider Ownership

CompanyInsider Ownership
Astrazeneca Plc stock logo
AZN
Astrazeneca
N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6.97%
CompanyEmployeesShares OutstandingFree FloatOptionable
Astrazeneca Plc stock logo
AZN
Astrazeneca
96,1001.55 billionN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,2002.41 billion2.40 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700394.94 million352.29 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.69 billion5.65 billionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,410105.72 million98.35 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Astrazeneca stock logo

Astrazeneca NYSE:AZN

$184.05 +2.81 (+1.55%)
As of 12:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$223.57 -1.98 (-0.88%)
As of 12:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Moderna stock logo

Moderna NASDAQ:MRNA

$48.52 +1.81 (+3.86%)
As of 12:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer stock logo

Pfizer NYSE:PFE

$26.28 -0.17 (-0.62%)
As of 12:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$718.84 +16.57 (+2.36%)
As of 12:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.